Full Breakdown
GSK Launches £1.9 bn Cost-Savings Programme and Shifts R&D to Cambridge
7/29/2026, 9:05:14 PM
Core Event
On July 28, GlaxoSmithKline announced a three-year “Accelerate Growth” programme targeting £1.9 billion of annual savings by 2029. The plan funds a £400 million investment in a new 300,000-sq-ft R&D centre on the Cambridge Biomedical Campus, where more than 1,000 scientists will be based. GSK will vacate its Stevenage hub, with staff relocation slated for completion by 2029.
Background & Context
The restructuring follows the appointment of Luke Miels as chief executive on January 1, succeeding Emma Walmsley. Miels’ agenda centres on mitigating the patent cliff for the HIV drug dolutegravir, whose U.S. exclusivity expires between 2028 and 2030, and on accelerating late-stage development of seven experimental medicines across 18 indications.
Timeline
- January 1 – Luke Miels assumes the CEO role.
- July 28 – Cost-savings programme and Cambridge R&D investment unveiled.
- 2026 (end) – Target to start 25 late-stage studies, more than double the previous goal of 10.
- 2029 – Planned closure of the Stevenage site and completion of the phased staff move to Cambridge and upgraded Ware facilities.
Data & Statistics
- £1.9 bn annual savings target (? $2.5 bn) by 2029.
- £2.4 bn one-time implementation cost.
- £400 m allocated to the Cambridge centre over three years.
- 300,000 sq ft site housing >1,000 scientists.
- 20+ Phase III trials to be launched this year.
- 25 late-stage studies expected by the end of 2026.
- Q2 revenue £8.41 bn; core profit 50.5 p earnings per share, beating consensus.
- Share price reaction: reports range from a 4 % rise to up to 7 % on the day of the announcement.
Official Statements & Responses
Chief Scientific Officer Tony Wood highlighted the campus’s “exceptional opportunities for collaboration” and described the move as a catalyst for faster medicines discovery.
Verbatim Quotes
- “Mr Miels added: “This investment will accelerate our R&D and help us deliver new, competitive products.” — Tony Wood, Chief Scientific Officer, GSK
- “We’re not going to give a number today in terms of people changes, and that’s because I want the chance, and I want my team to have the chance, to discuss this with our people first,” — Luke Miels, CEO
- “Overall the ambition is heading in the right direction but we think the market will wait for delivery.” — Citi
What’s Next
- Complete the phased relocation of Stevenage staff to Cambridge and the upgraded Ware site by 2029.
- Launch the targeted 25 late-stage studies by the end of 2026.
- Pursue the £40 billion annual sales goal for 2031, relying on an expanded pipeline that includes oncology, respiratory, hepatology, vaccines and HIV assets.
